WASHINGTON, D.C. – The U.S. National Institutes of Health (NIH) and the Centers for Medicare & Medicaid Services have announced a joint effort to study the causes of autism spectrum disorder, ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results